Preventing Alzheimer's and Small Vessel Disease In the Aging Brain with Dr. Sandra Black

About this Video

• Video Title: Preventing Alzheimer's and Small Vessel Disease In the Aging Brain with Dr. Sandra Black
• Channel: Atria
• Speakers: Dr. Sandra Black, David (introducer)
• Duration: 01:06:33

Introduction

This video features a presentation by Dr. Sandra Black on preventing Alzheimer's disease and small vessel disease in the aging brain. Dr. Black discusses the prevalence of these conditions, their interconnectedness, and the latest research on their underlying mechanisms and potential treatments. The presentation also covers lifestyle factors that contribute to or mitigate the risks of these diseases.

Key Takeaways

• Comorbidity of Neurodegenerative and Vascular Diseases: Alzheimer's and small vessel disease frequently coexist in aging and dementia. Advanced neuroimaging and biomarkers allow for more precise diagnosis.
• Vascular Health is Crucial: Maintaining vascular health through lifestyle choices (diet, exercise, sleep, social engagement) is essential in preventing Alzheimer's and small vessel disease. Even light activity, such as 7000 steps daily, shows positive brain health benefits.
• The Neurogliovascular Unit: The brain's health depends on a healthy neurogliovascular unit, encompassing neurons, glial cells, and blood vessels. The intricate vascular network plays a vital role in oxygen and glucose delivery, immune response, and waste removal.
• Amyloid and Tau Proteins: While amyloid and tau proteins are implicated in Alzheimer's, they also have protective roles. Their dysregulation, however, contributes to neurodegeneration. Other misfolded proteins like TDP-43 often coexist, highlighting the complexity of the disease.
• Small Vessel Disease: Various forms of small vessel disease impact the brain's arteries and veins, leading to white matter hyperintensities, which correlate with cognitive decline. Venous involvement and remodeling are significant but often overlooked factors.
• Emerging Treatments: Disease-modifying therapies targeting amyloid (like lecanemab) show promise in preventing or slowing disease progression. However, potential adverse events, such as bleeding, underscore the need for careful monitoring and personalized approaches. Fluid biomarkers are also becoming valuable diagnostic tools.